Milrinone has been assigned to pregnancy category C by the FDA. Animal studies failed to reveal evidence of teratogenicity at doses approximately 2.5 times the recommended human dosage. Studies have revealed increased resorption rates. There are no adequate or well-controlled studies during human pregnancy. Milrinone should only be given during pregnancy when benefit outweighs risk.

Placental transfer of milrinone was noted (baboon) when loading and continuous intravenous doses resulting in plasma concentrations considered therapeutic in human were administered. The maternal to fetal baboon serum ratio was approximately 4:1 during 3 hours of infusion.

See references

There are no data on the excretion of milrinone into human milk.

See references